The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer. Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic and with ATP-site inhibitors. The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases. The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft. mTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access. In vitro biochemistry shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site. Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access. The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.
The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer. Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic and with ATP-site inhibitors. The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases. The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft. mTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access. In vitro biochemistry shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site. Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access. The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.
The mTOR pathway controls cell growth in response to energy, nutrients, growth factors and other environmental cues, and it figures prominently in cancer 1, 2 . Central to the pathway is the mTOR protein, which belongs to the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family 3 . mTOR assembles into two complexes with distinct inputs and downstream effects. mTOR complex 1 (mTORC1) is defined by its RAPTOR subunit [4] [5] [6] , which is replaced by RICTOR in mTOR complex 2 6, 7 (mTORC2). Both complexes also contain the requisite mLST8 subunit 8, 9 , but they differ in a number of other subunits that interact with RAPTOR or RICTOR 1 . mTORC1 regulates cell growth by promoting translation, ribosome biogenesis and autophagy 1, 4, 5 . Its activation requires nutrients and amino acids, which result in the RAPTOR-mediated recruitment of mTORC1 to lysosomes and late endosomes 10, 11 , and co-localization with its activator, the small GTPase RHEB 12, 13 . Ways in which RHEB is proposed to act include binding to and activating the mTOR kinase domain 14 , and displacing the mTORC1 inhibitor PRAS40 from RAPTOR 15, 16 . RHEB in turn is negatively regulated by the GTPaseactivating domain of the TSC2 tumour suppressor, which relays signals from multiple growth factor and stress pathways 17 . mTORC1 substrates include the eIF4E-binding protein 1 (4E-BP1) and ribosomal S6 kinases (S6K), which control cap-dependent translation initiation and elongation, respectively 18 . Phosphorylation of 4E-BP1 and S6K1 is dependent on their Tor signalling sequence (TOS) motif 19, 20 , which binds to RAPTOR and is also present in the negative regulator PRAS40 21, 22 . mTORC2 responds primarily to growth factors, promoting cellcycle entry, cell survival, actin cytoskeleton polarization and anabolic output 6, 7, 23 . Its substrates include the Ser/Thr protein kinases AKT, SGK and PKC, which share the hydrophobic motif phosphorylation site with S6K1 1,2 . Rapamycin, which forms a ternary complex with the FK506-binding protein 12 (FKBP12) and the FRB domain of mTOR, is thought to be an allosteric inhibitor 24, 25 . Rapamycin-FKBP12 inhibits mTORC1 to a variable extent that is substrate and phosphorylation-site dependent 25 , and it does not bind to mTORC2 23 . To overcome these limitations, ATP-competitive inhibitors that potently and uniformly inhibit both mTORC1 and mTORC2 are being developed as anticancer agents 26 . The six mammalian PIKKs regulate diverse cellular processes 27 . They share three regions of homology consisting of a ,600-residue FAT domain (named after FRAP, ATM and TRRAP), a ,300-residue PIKK catalytic domain and a ,35-residue FATC domain at the carboxy terminus 28 . In mTOR, the ,100-residue FRB domain is thought to occur between the FAT domain and the catalytic domain, and the region amino terminal to the FAT domain is required for binding to RAPTOR and RICTOR 1 . Here we present the crystal structure at 3.2 Å of a ,1,500-aminoacid mTOR-mLST8 complex containing the FAT, FRB, kinase and FATC domains, as well as the structures of this complex bound to an ATP transition state analogue and, respectively, ATP-competitive inhibitors. We discuss their implications for understanding mTOR function, regulation and inhibition by rapamycin and ATP-competitive compounds.
Overall structure of mTOR

DN
-mLST8
Crystals were grown using N-terminally truncated human mTOR (residues 1376-2549; hereafter mTOR DN ) bound to full-length human mLST8 (Supplementary Table 1 ). The complex was produced in an HEK293-F cell line that was stably transfected sequentially by Flagtagged mLST8 and Flag-tagged mTOR DN vectors. The kinase activity of mTOR DN -mLST8 is overall comparable to that of mTORC1 (Supplementary Fig. 1 ). mTORC1 is more active towards low-micromolar concentrations of S6K1 ki (kinase-inactive mutant) and 4E-BP1, consistent with RAPTOR recruiting these substrates through their TOS motifs, whereas mTOR DN -mLST8 is more active at higher substrate concentrations.
The mTOR DN -mLST8 structure has a compact shape (Fig. 1) . The FAT domain, which consists of a-a-helical repeats, forms a 'C'-shaped a-solenoid that wraps halfway around the kinase domain and clamps onto it. mLST8 and the FRB domain protrude from the kinase domain, on opposite sides of the catalytic cleft. The FATC domain is integral to the kinase domain structure.
The ,550-residue mTOR kinase domain adopts the two-lobe structure that is characteristic of both the PI3K and canonical protein kinase families 29 . It consists of an N-terminal lobe (N lobe), a larger C-terminal lobe (C lobe) and a cleft between the two that binds to ATP. The mTOR kinase domain contains the core PI3K kinase domain fold, but with substantial differences. Whereas PI3K kinase domain structures superimpose essentially across their entire ,350 residues, only ,250 residues of the mTOR kinase domain superimpose on PI3Ks (Supplementary Table 2 ). In addition, the mTOR kinase domain contains ,200 additional residues of insertions that decorate the common fold. The largest of these is the FRB domain (residues 2021-2118), which is inserted within the kinase N lobe (Fig. 1) . There is also a ,40-residue insertion in the C lobe that forms the binding site for mLST8 (residues 2258-2296; hereafter LBE).
Kinase domain structure
The mTOR kinase domain structure starts before the FRB domain, with the long ka1 helix ('k' denoting kinase domain) that is present in PI3Ks as well ( Fig. 2a and Supplementary Fig. 2a ). The ka1 helix is integral to the structure of the N lobe, because it packs in the concave surface of the N-lobe b-sheet in both mTOR and PI3Ks 29 . The FRB insertion occurs immediately after the ka1 helix. It is followed by a b-strand and two short helices that pack with the base of the FRB and replace the ka2 helix of the PI3K kinase domain fold. Thereafter, the mTOR and PI3K N lobes have similar structures.
The mTOR structure indicates that the ka1 helix is present in all PIKKs ( Supplementary Fig. 3a) . The SMG1, DNA-PKcs and TRRAP PIKKs also seem to have an FRB-like domain, because they respectively contain insertions of 128, 95 and 128 residues that are predicted to be a-helical. This is supported by the 6.6 Å X-ray diffraction data of DNA-PKcs reported recently 30 . Although the deposited DNA-PKcs model 30 , which contains a PI3K-derived kinase domain, lacks the FRB insertion, a reinterpretation of the data using the mTOR structure reveals electron density indicative of an FRB-like four-helix bundle ( Supplementary Fig. 3b ). ATM and ATR seem to lack a comparable insertion.
In the C lobe, the vicinity of the catalytic cleft contains four structural insertions in the PI3K core structure (LBE, kaAL, ka9b and FATC; Fig. 2a ). These form a spine of interactions centred on the activation loop, which is a ,30 residue segment with a central role in the function and regulation of canonical protein kinases. It forms part of the polypeptide-binding site, provides an active-site residue and undergoes a conformational change, typically a disorder-to-order transition, on kinase activation 31 . The activation loop is thought to have an analogous role in PI3Ks, among which it is ordered in only the class III PIK3C3 structures 32 . In the mTOR structure, the entire activation loop is well ordered (Supplementary Fig. 2b ) and its middle portion contains the kaAL helix insertion. One side of the activation loop packs with the ka9b insertion, and the other side packs with the FATC (Fig. 2a) . The FATC is not unique to PIKKs in its entirety, because its N-terminal half forms a helix (ka11) that is also present in PI3K structures 29, 32 . Its C-terminal half, which is absent from PI3Ks, forms three short helices that pack with the activation loop on one side and with the LBE on the other (Fig. 2a) .
The interactions that the FATC makes with the activation loop suggest that it may have a role in stabilizing the activation loop structure, and the LBE, through its interactions with the FATC, may contribute to this indirectly ( Supplementary Fig. 4a ). The FATC and activation loop sequences are highly conserved among PIKKs. Although the LBE is not conserved, all PIKK family members contain an LBE-like insertion that may similarly pack with FATC ( Supplementary Fig. 3a ).
The ka9b insertion (residues 2425-2436) plugs one end of the catalytic cleft ( Fig. 2a) . It partly overlaps with a segment, called the negative regulatory domain (residues 2430-2450), whose deletion activates mTOR in vitro 33 and in vivo 34, 35 . After ka9b, there is a 55-residue unstructured segment (residues 2437-2491) that is not conserved and has variable length in mTOR orthologues ( Supplementary Fig. 2a ).
Active-site conformation
To assess the activation state of the kinase domain structure and investigate the mechanism of phosphotransfer, we co-crystallized mTOR DN -mLST8 with ADP, Mg 21 and MgF 3
2
, a mimic of the c-phosphate group of ATP in the transition state 36 (Supplementary Table 1 ). The F o 2 F c map of these crystals at 3.5 Å shows strong electron density extending from the b-phosphate group of ADP, consistent with a bound MgF 3 2 group (Fig. 2b) . The presence of two additional Mg 21 ions is supported by the anomalous dispersion maps of apo-crystals soaked in AMPPNP-Mn 21 ( Supplementary Fig. 4b ). A superposition with the protein kinase CDK2 bound to the same ATP transition state mimic 36 reveals that the arrangement of key activesite residues and MgF 3 2 is remarkably conserved in mTOR ( Fig. 2c and Supplementary Fig. 4c ). These include the C-lobe Asn 2343 and Asp 2357, which in both mTOR and protein kinases serve as metal ligands, and Asp 2338, which in protein kinases has a key catalytic role in orienting and activating the substrate hydroxyl group for nucleophilic attack 36, 37 . The mTOR-CDK2 superposition also reveals a coincidence of the mTOR His 2340 and CDK2 Lys 129 side chains (Fig. 2c) . In protein kinases, a basic residue at this position interacts with both the substrate hydroxyl group and the c-phosphate transition state mimic, and is postulated to stabilize the build-up of charge at the transition state 36, 37 . Consistent with a similar role, we find that the kinase activity of the His2340Ala mTOR DN -mLST8 mutant is barely detectable, and comparable to the Asp2338Ala mutant previously shown to be inactive 38 ( Supplementary Fig. 4d ).
These findings strongly suggest that the crystallized mTOR DNmLST8 complex is intrinsically active in the absence of any additional regulatory subunits. They also indicate that PIKKs, and most probably PI3Ks, use the same catalytic mechanism as canonical protein kinases, in contrast to a recently proposed PI3K mechanism 32 ( Supplementary  Fig. 4c ).
Substrate-binding site
The MgF 3 2 c-phosphate mimic points to an extended C-lobe groove that is highly conserved and is the likely site of substrate binding. 
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Figure 2d illustrates this with a CDK2-bound substrate peptide docked by superposing the mTOR and CDK2 transition state 36 complexes. The groove consists of the activation loop, as in protein kinases, but also of portions of the FATC and LBE.
Carboxy-terminal to the phosphorylation site (the 1 direction), the groove extends only to the 11 position, abruptly terminating with the ka9b helix that plugs this end of the cleft (Fig. 2d) . Thereafter, the peptide can exit along the C lobe towards mLST8 or along the N lobe towards the FRB. The 11 portion of the groove has a pronounced pocket lined with three aromatic residues, consistent with the two classes of mTOR substrates-exemplified by 4E-BP1 and S6K1-that have a proline and a tyrosine residue, respectively, at 11 ( Supplementary  Fig. 5a, b) . The groove extends considerably more in the direction N-terminal to the phosphorylation site (the 2 direction), and it may account for the low-level sequence preference at 24 and 25 suggested by a positional scanning peptide array 39 .
Restricted access to the active site
The four-helix FRB substantially extends the N-lobe side of the catalytic cleft, whereas the LBE and mLST8 extend the C-lobe side. This gives the cleft a deep, 'V'-shaped cross-section, restricting access to the substrate-binding site at the bottom of the cleft (Fig. 3a) . Substrate access is further hindered by one end of the cleft being plugged by ka9b and the 55-residue unstructured segment that follows the helix. Portions of ka9b and the unstructured segment form the negative regulatory region [33] [34] [35] , suggesting that restricted access to the active site negatively regulates mTOR. Helix ka9b is probably the key element because deleting the bulk of the unstructured segment (residues 2443-2486) does not activate mTOR ( Supplementary Fig. 6 ).
The end of the cleft opposite ka9b is unencumbered in the mTOR DN -mLST8 structure. However, it is near the FAT N terminus, and the region deleted from the crystallized mTOR DN may restrict cleft access directly or through its associated RAPTOR or RICTOR proteins, or by both means. In support, we find that towards TOS mutant 4E-BP1 and S6K1 ki substrates, mTOR DN -mLST8 is more active than mTORmLST8, which in turn is more active than mTOR-mLST8-RAPTOR (Supplementary Fig. 6 ). A restricted active site would reduce the probability of substrates hitting the active site by random diffusion, and could thus be important in allowing for the regulation of phosphorylation by substrate recruitment.
Inhibition by rapamycin-FKBP12
In a model constructed by superposing the FRB domains of the FRBrapamycin-FKBP12 24 and mTOR DN -mLST8 structures, FKBP12 extends from the FRB towards mLST8 on the C lobe, nearly capping the catalytic cleft (Fig. 3b) . At their closest approach, FKBP12 and mLST8 are only 8 Å apart, with the catalytic centre recessed by 37 Å . The model suggests that rapamycin-FKBP12 inhibits in part by drastically reducing the accessibility of the already constricted catalytic cleft. This is consistent with the extent of mTORC1 inhibition being 
ARTICLE RESEARCH
substrate and phosphorylation-site dependent 25 (additional discussion in Supplementary Fig. 6 legend) .
FRB recruits S6K1 to the active site
The rapamycin-binding site maps to the FRB surface closest to the active site, in a region of highly conserved residues (Fig. 4a) . Four of these residues are invariant in 22 mTOR orthologues from yeast to human, and another four in 21 orthologues, in stark contrast to the FRB surface opposite the active site ( Fig. 4a and Supplementary Fig. 7 ). This raises the possibility that the rapamycin-binding site interacts with substrates to facilitate their entry to the recessed active site. This model is supported by the observation that mutation of Ser 2035, a rapamycin contact 38, 40 at the centre of the conservation region, reduces phosphorylation of S6K1 and 4E-BP1 33 . It can also explain inhibition of mTORC1 and mTORC2 by rapamycin in the absence of FKBP12, albeit at ,100-fold-higher concentrations reflecting the weaker rapamycin-FRB binary interaction 41 . However, these observations can also be explained by the rapamycin-binding site interacting with other parts of mTOR, or with associated proteins, especially because rapamycin was thought to be an allosteric inhibitor 25 . To rule this out, we assayed mTOR DN -mLST8 and found that rapamycin, but not the closely related FK506 macrolide, inhibits S6K1 ki overall phosphorylation, as measured by 32 P incorporation (Fig. 4b) . Inhibition reaches ,45% at the 20 mM solubility limit of rapamycin, close to the free rapamycin-FRB dissociation constant. Phosphorylation of the key Thr 389 site of the S6K1 hydrophobic motif, measured by a phospho-Thr-389-specific antibody, is inhibited by ,80% (Fig. 4b) .
In a complementary approach, we tested whether the isolated FRB domain inhibits phosphorylation in trans. Figure 4c shows that wildtype FRB but not the Ser2035Ile FRB mutant 38, 40 inhibits overall S6K1 ki phosphorylation by ,50% and Thr 389 phosphorylation by ,75% at the highest concentration tested.
To map the region of S6K1 involved in FRB interactions, we reasoned that its deletion should reduce Thr 389 phosphorylation and also render any residual phosphorylation insensitive to rapamycin. By testing successively truncated polypeptides from the S6K1 tail, we found that both criteria are met by residues 393-398 (Fig. 4d) . In addition, residues 399-402 and 403-410 probably contribute to FRB interactions, because their truncation progressively reduces phosphorylation (Supplementary Fig. 8 ). Amino-terminal truncations up to residue 381 have no significant effect.
Together, these data indicate that the FRB provides a secondary substrate-recruitment site near the entrance of the catalytic cleft. We presume that, although the TOS motif, and possibly others, is the primary means of substrate recruitment, the secondary site may facilitate substrate entry into the otherwise restricted active site and may also provide an additional level of specificity, at least for a subset of substrates.
A bipartite substrate-recruitment mechanism is analogous to what has been proposed for the phosphatase calcineurin, the target of 
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FK506-FKBP12. Most calcineurin substrates require both a primary and a secondary recruitment motif for efficient dephosphorylation, and FK506-FKBP12 inhibits by binding to the secondary recruitment motif site 42 .
FAT domain
The FAT domain contains 28 a-helices arranged as a-a-helical repeats. Helices a1 to a22 belong to the TPR repeat family and form three discontinuous domains (TRD1, TRD2 and TRD3). Helices a23 to a28 belong to the HEAT family and form a single domain (HRD). The four domains pack sequentially to form a 'C'-shaped a-solenoid that clamps onto the kinase domain ( Supplementary Fig. 9a, b ). TRD1 interacts with the C lobe on one side of the kinase domain, and after TRD2 and TRD3 traverse to the other side, the HRD interacts with both the N lobe and the C lobe of the kinase domain ( Supplementary  Fig. 9c, d ).
The contacts TRD1 and HRD make to the kinase domain involve conserved residues, consistent with the two interfaces being important for the structure and function of mTOR. For example, three sets of buried hydrogen bond contacts (Glu 1401 to Arg 2317 for TRD1, and Arg 1905 to Glu 2419 and Gln 1941 to Gln 2200 for HRD) involve residues invariant in 22 mTOR orthologues ( Supplementary Fig. 9c, d) .
The TRD1 and HRD segments correspond to the FAT segments best conserved among PIKK family members 28 as well, suggesting that the FAT domain clamping onto the kinase domain is a common feature of this family. In addition, PI3Ks contain a HEAT-repeat domain analogous to the HRD in its structure and interactions with the kinase domain, although they lack the rest of the FAT domain ( Supplementary Fig. 9e ). mLST8 mLST8 consists of seven WD40 repeats. At the narrow end of the mLST8 b-propeller structure, a surface that extends across six WD40 repeats binds to both helices and the intervening loop of the LBE helix-loop-helix structure. The interface involves mostly polar LBE residues and polar or aromatic mLST8 residues, and it is dominated by hydrogen bonds (Supplementary Fig. 10 ).
mLST8 is thought to be a requisite activating subunit of mTOR complexes 8, 9 . The structure suggests that the extended interaction surface of mLST8 may directly stabilize the LBE structure and indirectly influence the organization of the active site through the LBE/ FATC/activation-loop spine of interactions ( Supplementary Fig. 4a ). In support of this, we note that lack of mLST8 results in the association of mTOR with heat shock proteins 9 , and we find that the solubility of overexpressed mTOR is highly dependent on mLST8 co-expression (not shown). In addition, the growth-suppression phenotype of a temperature-sensitive yeast lst8 allele can be rescued by mutations 43 either at the LBE hydrophobic core (Ala2290Val) or at the following ka5 helix (Leu2302Gln), and the structure is consistent with these mutations stabilizing the local LBE structure.
Control of mTOR kinase activity
The proposal that active-site restriction is a negative regulatory mechanism is supported by hyperactivating mutations [43] [44] [45] , most of which map to structural elements involved in limiting active-site access. A large number of mutations cluster at the end of the catalytic cleft that is plugged by ka9b ( Fig. 5 and Supplementary Fig. 11 ). They map to the ka3, ka9, ka9b and ka10 helices that pack extensively with each other, and to the FAT HRD portion that packs with ka3 and ka9. These mutations are likely to loosen the ka9b-centred structural framework that restricts access from this end of the cleft, presumably without destabilizing the entire active-site structure. The role of the FAT clamp is highlighted by the widely studied Glu2419Lys activating mutation, which eliminates the Glu 2419/Arg 1905 salt bridge at the ka9-HRD interface (Supplementary Figs 9c and 11) .
Two other hyperactivating mutations map to a portion of the ka1 helix that is sandwiched between the FRB base and the N-lobe b-sheet 43, 44 . These mutations (Ile2017Val and Ala2020Val) are unlikely to unfold the FRB, because an FRB hydrophobic core mutation (Trp2027Phe) abolishes kinase activity 40 . The structure suggests that these mutations may loosen the rigid coupling of the FRB to the catalytic cleft, increasing access to the active site.
A third cluster of mutations 43 maps to the N-terminal portion of the FAT domain and to structural residues of TRD1 and the TRD1-proximal portion of TRD2. These mutations would probably destabilize interactions between TRD1 and the kinase domain through loss of structural integrity. They may also destabilize the interactions between HRD and the kinase domain, because the structural coupling of TRD1 and HRD would thermodynamically couple their kinase domain contacts. In addition, the disposition of the N-terminal mTOR segment and its associated RAPTOR could change or become more flexible relative to the kinase domain.
Inhibitors of the ATP-binding site
To explore the determinants of inhibitor potency and specificity, we determined the structures of mTOR DN -mLST8 bound to Torin2 and PP242, which are highly specific for mTOR, and to PI-103, which has dual specificity for mTOR and class I PI3Ks (Supplementary Table 3 ).
The overall orientation of Torin2 in the ATP site is as predicted 46 ( Fig. 6a and Supplementary Fig. 12a ). The tricyclic benzonaphthyridinone ring binds to the adenine site and makes a hydrogen bond with the 'hinge' between the N and C lobes, analogous to one of two backbone hydrogen bonds made by ATP and diverse inhibitors of PI3 or protein kinases. The aminopyridine group reaches into the 'inner hydrophobic pocket', an area at the back of the cleft that many kinase inhibitors 
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contact. However, it does not make the three predicted hydrogen bonds 46 (to Asp 2195, Asp 2357 and Tyr 2225). Rather, the structure reveals that a key interaction is the extensive stacking of the tricyclic benzonaphthyridinone ring with the indole group of Trp 2239 from the hinge (Fig. 6a) . In the ATPcS complex, Trp 2239 stacks partly with a three-atom portion of the adenine. In the Torin2 complex, by contrast, Trp 2239 stacks with a ten-atom portion of the tricyclic Torin2 ring. This probably makes a substantial contribution to the subnanomolar potency 46 of Torin2. In addition, because Trp 2239 is not present in canonical protein kinases or in PI3Ks, it would also contribute to the ,800-fold specificity of Torin2 for mTOR over PI3Ks 46 . The structure also reveals that the Torin2 trifluoromethyl group packs into an N-lobe pocket (Ile 2163, Pro 2169 and Leu 2185; Fig. 6a ). These contacts are less extensive than those made to Trp 2239, and only Leu 2185 is variable across the PIKK and PI3K families. They may contribute to Torin2-mTOR specificity, however, because this portion of the N-lobe b-sheet exhibits considerable variation in its relative orientation in PI3K structures.
PP242 consists of the adenine-mimetic pyrazolopyrimidine scaffold common to PI3 or tyrosine kinase inhibitors, with a hydroxyindole substituent at a position that often points to the inner hydrophobic pocket 47 . In mTOR, this pocket is lined with residues conserved across the PI3K and PIKK families, and the selectivity of PP242 for mTOR was unexpected 47 . The structure reveals that, although these two PP242 groups are generally positioned as predicted 47 , mTOR undergoes a conformational change that expands and deepens the inner hydrophobic pocket, with the PP242 hydroxyindole group reaching deep into the new space ( Fig. 6b and Supplementary Fig. 12b ). The conformational change involves the Tyr 2225 side chain at the back of the pocket swinging out of the way of the hydroxyindole group (by Dx 1 5 108u; Fig. 6c and Supplementary Fig. 12c ). Because Tyr 2225 is part of the local hydrophobic core between the N and C lobes, this necessitates additional concerted changes. The Leu 2354 side chain rotates away from the incoming Tyr 2225 (Dx 1 5 166u) , the Gln 2223 side chain moves in to plug a resulting gap and a three-residue main-chain stretch (residues 2223-2225) shifts by ,1 Å . In PI3Ks, Leu 2354 is replaced by a conserved phenylalanine that cannot undergo a similar conformational change, at least not without even more extensive repacking of the local hydrophobic core. Leu 2354 is thus likely to be a major, although indirect, determinant of the selectivity of PP242 for mTOR over PI3Ks and other kinases.
The multi-targeted pyridinylfuranopyrimidine inhibitor PI-103 48 does not take advantage of any of the aforementioned mTOR-specific features. The morpholine ring binds to the adenine pocket and makes two hydrogen bonds to the hinge, whereas the phenol group binds to the inner pocket and makes two hydrogen bonds to the Tyr 2225 and Asp 2195 side chains at the back of the cleft (Fig. 6d and Supplementary Fig. 12d ). These hydrogen bonds are likely to be important for the high affinity of PI-103 for mTOR and, presumably, for class I PI3Ks where the relevant protein groups are similarly positioned. In support of this, we note that the ,500-fold-weaker-affinity 48 class III PI3K/PI-103 complex lacks both phenol hydrogen bonds and one of the hinge hydrogen bonds 32 .
Conclusions
The mTOR DN structure reveals an intrinsically active but otherwise highly restricted catalytic centre, and, together with activating mutations, points to substrate recruitment as a major mechanism controlling the kinase activity. Our biochemical data on S6K1 indicate that in addition to a primary recruitment motif, a secondary recruitment motif proximal to the phosphorylation site is needed for efficient phosphorylation. The FRB acts as a gatekeeper by restricting access to the active site while also granting privileged substrates access through its binding site for the secondary motif. Co-crystal structures of ATP-competitive inhibitors reveal multiple determinants of mTOR specificity, including a conformational change deep inside the catalytic cleft.
METHODS SUMMARY
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